Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CORRECTION: Lipocine Q4 EPS $(0.03), Inline

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.
byHappy Mohamed
March 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder

By Akanksha Bakshi
October 23, 7:31 AM
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD).

ALZN